Pharmacogenomics of Cisplatin-Induced Toxicity in Children

  • Aadil Rasheed
  • Maliha Ghaffar
  • Hina SalahuddinEmail author


Cisplatin is a widely used chemotherapeutics agent used to treat cancers in all age groups. It induces apoptosis but is deactivated by some proteins that results in adverse side effects. It has been found to produce toxicity in children. Though it has a high cure rate, still the toxicity caused by cisplatin cannot be neglected. Cisplatin-induced ototoxicity and nephrotoxicity are major consequences of its side effects. It produces GST polymorphisms, megalin SNPs, thiopurine S-methyltransferase, and catechol-O-methyltransferase variants. An elevated ROS level is evident in all affected by cisplatin-induced ototoxicity. Similarly, different SNPs related to nephrotoxicity have also been reported. Comprehensive studies of other cisplatin-induced toxicity are yet to be carried out.


Cisplatin Pediatrics Pharmacogenomics Children Toxicity Chemotherapeutics Cancer Side effects 


  1. 1.
    Lippert B (ed) (1999) Cisplatin: chemistry and biochemistry of a leading anticancer drug. Wiley, Zürich, pp 3–27Google Scholar
  2. 2.
    Rosenberg B, Van Camp L, Krigas T (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698–699. Scholar
  3. 3.
    Rosenberg B, Van Camp L, Grimley EB, Thomson AJ (1967) The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J Biol Chem 242:1347–1352PubMedGoogle Scholar
  4. 4.
    Rosenberg B, Renshaw E, Vancamp L et al (1967) Platinum-induced filamentous growth in Escherichia coli. J Bacteriol 93:716–721CrossRefGoogle Scholar
  5. 5.
    Rosenberg B, Vancamp L, Trosko JE, Mansour VH (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222:385–386. Scholar
  6. 6.
    Rosenberg B, VanCamp L (1970) The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res 30:1799–1802PubMedGoogle Scholar
  7. 7.
    Peyrone (1845) Cisplatin. M Ann 51:15Google Scholar
  8. 8.
    Mellor DP (1943) The stereochemistry of square complexes. Chem Rev 33:137–183. Scholar
  9. 9.
    Kauffman G (1997) B Plat Met Rev 41:34–40Google Scholar
  10. 10.
    Werner A (1893) Beitrag zur Konstitution anorganischer Verbindungen. Z Anorg Chem 3:267–330. Scholar
  11. 11.
    Dhara SC (1970) Indian J Chem 8:193–134Google Scholar
  12. 12.
    Basolo F, Pearson RG (1967) Mechanisms of inorganic reactions: a study of metal complexes in solution. Wiley, New York, pp 351–453Google Scholar
  13. 13.
    Natile G, Coluccia M (2001) Coord Chem Rev 216–217:383410Google Scholar
  14. 14.
    Kauffman GB, Cowan DO, Slusarczuk G, Kirschner S (2007) Cis- and trans-Dichlorodiammineplatinum(II). In: Kleinberg J (ed) Inorganic syntheses. Wiley, Hoboken, pp 239–245CrossRefGoogle Scholar
  15. 15.
    Sigel A, Sigel H (eds) (2004) Metal ions and their complexes in medication. Marcel Dekker, New YorkGoogle Scholar
  16. 16.
    Vollano JF, Al-Baker S, Dabrowiak JC, Schurig JE (1987) J Med Chem 30:716–719CrossRefGoogle Scholar
  17. 17.
    Ellis L, Er H, Hambley T (1995) The influence of the axial ligands of a series of platinum(IV) anti-cancer complexes on their reduction to platinum(II) and reaction with DNA. Aust J Chem 48:793–806. Scholar
  18. 18.
    Galanski M, Keppler BK (1996) Carboxylation of dihydroxoplatinum(IV) complexes via a new synthetic pathway. Inorg Chem 35:1709–1711. Scholar
  19. 19.
    Ivanov AI, Christodoulou J, Parkinson JA et al (1998) Cisplatin binding sites on human albumin. J Biol Chem 273:14721–14730. Scholar
  20. 20.
    Silvestru C (1994) Metal complexes in cancer chemotherapy. B. K. Keppler (ed) VCH, Weinheim and New York, 1993, 429 pp. DM 196, ISBN 3-527-28425-7 (VCH, Weinheim); ISBN 1-56081-216-8 (VCH, New York). Appl Organomet Chem 8:499–500. Scholar
  21. 21.
    DeConti RC, Toftness BR, Lange RC, Creasey WA (1973) Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 33:1310–1315PubMedPubMedCentralGoogle Scholar
  22. 22.
    Kelland LR (2000) Preclinical perspectives on platinum resistance. Drugs 59(Suppl 4):1–8. Scholar
  23. 23.
    Desoize B (2002) Cancer and metals and metal compounds: part I--carcinogenesis. Crit Rev Oncol Hematol 42:1–3CrossRefGoogle Scholar
  24. 24.
    Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (2009) Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 219:177–186. Scholar
  25. 25.
    Mukherjea D, Rybak LP, Sheehan KE et al (2011) The design and screening of drugs to prevent acquired sensorineural hearing loss. Expert Opin Drug Discovery 6:491–505. Scholar
  26. 26.
    Tauris J, Christensen EI, Nykjaer A et al (2009) Cubilin and megalin co-localize in the neonatal inner ear. Audiol Neurootol 14:267–278. Scholar
  27. 27.
    Barnham KJ, Djuran MI, Murdoch P del S et al (1996) Ring-opened adducts of the anticancer drug carboplatin with sulfur amino acids. Inorg Chem 35:1065–1072. Scholar
  28. 28.
    Lempers ELM, Reedijk J (1991) Adv Inorg Chem 37:175–217CrossRefGoogle Scholar
  29. 29.
    Andrews PA, Wung WE, Howell SB (1984) A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate. Anal Biochem 143:46–56. Scholar
  30. 30.
    Dolman RC, Deacon GB, Hambley TW (2002) Studies of the binding of a series of platinum(IV) complexes to plasma proteins. J Inorg Biochem 88:260–267. Scholar
  31. 31.
    Borch RF, Pleasants ME (1979) Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. Proc Natl Acad Sci 76:6611–6614. Scholar
  32. 32.
    Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67:1171–1176. Scholar
  33. 33.
    Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci 99:14298–14302. Scholar
  34. 34.
    Davies MS, Berners-Price SJ, Hambley TW (2000) Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA. Inorg Chem 39:5603–5613. Scholar
  35. 35.
    Lippert B (ed) (1999) Cisplatin: chemistry and biochemistry of a leading anticancer drug. Wiley, Zürich, pp 183–206Google Scholar
  36. 36.
    Lippert B (ed) (1999) Cisplatin: chemistry and biochemistry of a leading anticancer drug. Wiley, Zürich, pp 207–222Google Scholar
  37. 37.
    Lippert B (ed) (1999) Cisplatin: chemistry and biochemistry of a leading anticancer drug. Wiley, Zürich, pp 223–246Google Scholar
  38. 38.
    Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467–2498CrossRefGoogle Scholar
  39. 39.
    Hambley TW (2001) Platinum binding to DNA: structural controls and consequences. J Chem Soc Dalton Trans 2001:2711–2718. Scholar
  40. 40.
    Cohen GL, Ledner JA, Bauer WR, Ushay HM, Caravana C, Lippard SJ (1980) J Am Chem Sot 102:2487–2488CrossRefGoogle Scholar
  41. 41.
    Fuertes MA, Castilla J, Alonso C, Pérez JM (2002) Novel concepts in the development of platinum antitumor drugs. Curr Med Chem Anticancer Agents 2:539–551CrossRefGoogle Scholar
  42. 42.
    Mizuta K, Saito A, Watanabe T et al (1999) Ultrastructural localization of megalin in the rat cochlear duct. Hear Res 129:83–91. Scholar
  43. 43.
    Riedemann L, Lanvers C, Deuster D et al (2008) Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 8:23–28. Scholar
  44. 44.
    Ross CJD, Katzov-Eckert H, Dubé M-P et al (2009) Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 41:1345–1349. Scholar
  45. 45.
    el Barbary A, Altschuler RA, Schacht J (1993) Glutathione S-transferases in the organ of Corti of the rat: enzymatic activity, subunit composition and immunohistochemical localization. Hear Res 71:80–90. Scholar
  46. 46.
    Touliatos JS, Neitzel L, Whitworth C et al (2000) Effect of cisplatin on the expression of glutathione-S-transferase in the cochlea of the rat. Eur Arch Otorhinolaryngol 257:6–9CrossRefGoogle Scholar
  47. 47.
    Fujimura T, Suzuki H, Udaka T et al (2008) Immunoreactivities for glutathione S-transferases and glutathione peroxidase in the lateral wall of pigmented and albino guinea pig cochlea. Med Mol Morphol 41:139–144. Scholar
  48. 48.
    Peters U, Preisler-Adams S, Hebeisen A et al (2000) Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anti-Cancer Drugs 11:639–643CrossRefGoogle Scholar
  49. 49.
    Oldenburg J, Kraggerud SM, Cvancarova M et al (2007) Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 25:708–714. Scholar
  50. 50.
    Pussegoda KA (2010) Genetic variants associated with cisplatin-induced hearing loss. Clin Genet 78:33–35. Scholar
  51. 51.
    Peters U, Preisler-Adams S, Lanvers-Kaminsky C et al (2003) Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Res 23:1249–1255PubMedGoogle Scholar
  52. 52.
    Caronia D, Patiño-García A, Milne RL et al (2009) Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 9:347–353. Scholar
  53. 53.
    Zazuli Z, Vijverberg S, Slob E et al (2018) Genetic variations and cisplatin nephrotoxicity: a systematic review. Front Pharmacol 9:1111. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Aadil Rasheed
    • 1
  • Maliha Ghaffar
    • 1
  • Hina Salahuddin
    • 1
    Email author
  1. 1.Department of ZoologyUniversity of OkaraOkaraPakistan

Personalised recommendations